Wang Youming, Jia Weibing, Wang Minjia, Yang Xiaoli, Gao Xinli, Zhang Yao
Hebei University of Engineering, Handan 056107, Hebei Province, China; Department of Neurology, Affiliated Hospital of Hebei Engineering University, No.81 Congtai Road, Congtai District, Handan 056002, Hebei Province, China.
School of Clinical Medicine, Hebei University of Engineering, Handan 056002, Hebei Province, China.
J Neurol Sci. 2024 Dec 15;467:123326. doi: 10.1016/j.jns.2024.123326. Epub 2024 Nov 23.
To describe the clinical characteristics, therapeutic approaches, and prognostic outcomes of osmotic demyelination syndrome (ODS) in cancer patients.
A comprehensive literature search (January 1950-March 2024) using PubMed, Embase, Cochrane Library, and Web of Science. Keywords included "osmotic demyelination and cancer", "central pontine myelinolysis and cancer", and "extrapontine myelinolysis and cancer", "Osmotic demyelination and malignancy," "Central pontine myelinolysis and malignancy," and "Extrapontine myelinolysis and malignancy." References from selected articles were manually reviewed for inclusion. Studies involving benign lesions, surgical interventions, non-malignant ODS, and ODS of unknown etiology without malignancy were excluded.
A total of 22 cases of cancer-complicated ODS were identified in the literature. The median age of onset was 55 years, with no observed gender differences. Clinical presentations ranged from completely asymptomatic (4.5 %,1/22) to disorders of consciousness (27.3 %, 6/22). Notably, 22.7 % (5/22) of patients initially presented with either no symptoms or non-specific symptoms (seizures, abnormal mental behavior) that could be mistaken for hyponatremia itself. Furthermore, 90 % of patients did not experience rapid sodium correction, and 59.1 % received only symptomatic therapy or treatment of the primary cancer. Only 9.1 % of patients received immunoglobulin or plasma exchange, which may improve outcomes.
Osmotic demyelination syndrome represents a potential complication in cancer patients, potentially arising from complex interactions. Clinical manifestations are highly variable and often under-recognized, particularly by non-neurologists. Traditional sodium correction protocols may still induce ODS in cancer patients, suggesting a need for cautious sodium management. Timely diagnosis and appropriate intervention are crucial for determining patient prognosis.
描述癌症患者渗透性脱髓鞘综合征(ODS)的临床特征、治疗方法及预后结果。
利用PubMed、Embase、Cochrane图书馆和Web of Science进行全面的文献检索(1950年1月至2024年3月)。关键词包括“渗透性脱髓鞘与癌症”、“脑桥中央髓鞘溶解与癌症”、“脑桥外髓鞘溶解与癌症”、“渗透性脱髓鞘与恶性肿瘤”、“脑桥中央髓鞘溶解与恶性肿瘤”以及“脑桥外髓鞘溶解与恶性肿瘤”。对所选文章的参考文献进行人工审核以确定是否纳入。排除涉及良性病变、手术干预、非恶性ODS以及病因不明且无恶性肿瘤的ODS的研究。
文献中总共确定了22例癌症并发ODS的病例。发病年龄中位数为55岁,未观察到性别差异。临床表现从完全无症状(4.5%,1/22)到意识障碍(27.3%,6/22)不等。值得注意的是,22.7%(5/22)的患者最初表现为无症状或非特异性症状(癫痫发作、异常精神行为),可能被误诊为低钠血症本身。此外,90%的患者未经历快速纠正钠,59.1%的患者仅接受了对症治疗或原发性癌症的治疗。只有9.1%的患者接受了免疫球蛋白或血浆置换,这可能改善预后。
渗透性脱髓鞘综合征是癌症患者的一种潜在并发症,可能由复杂的相互作用引起。临床表现高度可变,且常常未被充分认识,尤其是非神经科医生。传统的钠纠正方案仍可能在癌症患者中诱发ODS,这表明需要谨慎进行钠管理。及时诊断和适当干预对于确定患者预后至关重要。